Result of AGM

Cambridge Antibody Tech Group PLC
30 January 2004


For Immediate Release

Friday 30 January 2004

For further information contact:         Weber Shandwick Square Mile(Europe)
Cambridge Antibody Technology            Tel: [phone]
Tel: [phone]                Kevin Smith
Peter Chambre, Chief Executive Officer   Rachel Lankester
John Aston, Chief Financial Officer      
Rowena Gardner, Director of Corporate    BMC Communications/The Trout Group(USA)
Communications                           Tel: [phone]
                                         Brad Miles, ext 17 (media)
                                         Brandon Lewis, ext 15 (investors)


CAMBRIDGE ANTIBODY TECHNOLOGY GROUP PLC
REPORTS OUTCOME OF 2004 ANNUAL GENERAL MEETING

Cambridge, UK...Cambridge Antibody Technology (LSE: CAT, NASDAQ: CATG) reports
that at its Annual General Meeting, held at 12:30 GMT on Friday 30 January 2004,
all resolutions were duly passed.

                                     -ENDS-

Notes to Editors

Cambridge Antibody Technology (CAT):

   • CAT is a UK-based biotechnology company using its proprietary
    technologies and capabilities in human monoclonal antibodies for drug
    discovery and drug development. Based near Cambridge, England, CAT currently
    employs around 270 people.
   • CAT is a leader in the discovery and development of human therapeutic
    antibodies and has an advanced proprietary platform technology for rapidly
    isolating human monoclonal antibodies using phage display and ribosome
    display systems. CAT has extensive phage antibody libraries, currently
    incorporating more than 100 billion distinct antibodies. These libraries
    form the basis for the Company's strategy to develop a portfolio of
    antibody-based drugs.
   • Three CAT human therapeutic antibody products are now in clinical
    development, with two further product candidates in pre-clinical
    development.
   • HUMIRATM, the leading CAT-derived antibody, isolated and optimised in
    collaboration with Abbott has been approved by the US Food and Drug
    Administration for marketing in the US and by the European Commission for
    marketing in the EU as a treatment for rheumatoid arthritis.
   • Five further licensed CAT-derived human therapeutic antibodies in
    clinical development, with three further licensed product candidates in
    pre-clinical development.
   • CAT has alliances with a number of pharmaceutical and biotechnology
    companies to discover, develop and commercialise human monoclonal
    antibody-based products. CAT has co-development programmes with Amrad, Elan
    and Genzyme.
   • CAT has also licensed its proprietary technologies to several companies.
    CAT's licensees include: Abbott, Amgen, Chugai, Human Genome Sciences, Merck
    & Co, Pfizer and Wyeth Research.
   • CAT is listed on the London Stock Exchange and on NASDAQ since June
    2001. CAT raised £41m in its IPO in March 1997 and £93m in a secondary
    offering in March 2000.
   • CAT and Lonza Biologics announced their earlier long term agreement for
    the manufacture and supply of clinical grade antibodies on 26 November 2001.


Application of the Safe Harbor of the Private Securities Litigation Reform Act
of 1995: This press release contains statements about Cambridge Antibody
Technology Group plc ("CAT") that are forward looking statements. All statements
other than statements of historical facts included in this press release may be
forward looking statements within the meaning of Section 21E of the Securities
Exchange Act of 1934. These forward looking statements are based on numerous
assumptions regarding the company's present and future business strategies and
the environment in which the company will operate in the future. Certain factors
that could cause the company's actual results, performance or achievements to
differ materially from those in the forward looking statements include: market
conditions, CAT's ability to enter into and maintain collaborative arrangements,
success of product candidates in clinical trials, regulatory developments and
competition. We caution investors not to place undue reliance on the forward
looking statements contained in this press release. These statements speak only
as of the date of this press release, and we undertake no obligation to update
or revise the statements.




                      This information is provided by RNS
            The company news service from the London Stock Exchange